GSA Capital Partners LLP Decreases Holdings in Allogene Therapeutics, Inc. $ALLO

GSA Capital Partners LLP reduced its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 62.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 182,879 shares of the company’s stock after selling 309,242 shares during the quarter. GSA Capital Partners LLP owned 0.08% of Allogene Therapeutics worth $227,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ALLO. Vanguard Group Inc. lifted its stake in Allogene Therapeutics by 9.2% in the third quarter. Vanguard Group Inc. now owns 9,020,770 shares of the company’s stock valued at $11,186,000 after purchasing an additional 761,642 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Allogene Therapeutics by 177.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after buying an additional 3,747,397 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of Allogene Therapeutics by 16.0% during the 2nd quarter. Primecap Management Co. CA now owns 5,719,140 shares of the company’s stock valued at $6,463,000 after buying an additional 787,300 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Allogene Therapeutics by 13.0% during the 2nd quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after acquiring an additional 435,389 shares during the period. Finally, Patient Square Capital LP increased its holdings in Allogene Therapeutics by 11.3% in the 2nd quarter. Patient Square Capital LP now owns 2,635,000 shares of the company’s stock worth $2,978,000 after acquiring an additional 266,814 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total value of $40,304.00. Following the transaction, the senior vice president owned 564,948 shares of the company’s stock, valued at $994,308.48. This represents a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David D. Chang sold 95,269 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total transaction of $171,484.20. Following the sale, the chief executive officer owned 5,185,862 shares in the company, valued at approximately $9,334,551.60. This trade represents a 1.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 215,855 shares of company stock worth $378,426. Insiders own 13.20% of the company’s stock.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $2.78 on Friday. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.80. The stock has a market cap of $624.75 million, a P/E ratio of -2.84 and a beta of 0.60. The firm’s fifty day moving average price is $1.71 and its 200-day moving average price is $1.41.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. UBS Group started coverage on shares of Allogene Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Friday, January 9th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.